SIRVA, or Shoulder Injury Related to Vaccine Administration, is a shoulder injury caused not by the vaccine itself but by the needle being inserted too high or too deep into the shoulder during injection. Instead of depositing the vaccine into the deltoid muscle where it belongs, the needle penetrates deeper structures like the bursa (a fluid-filled cushion between the muscle and bone), the rotator cuff tendons, or the joint lining. The result is pain and limited movement that can persist for months or longer, far beyond the day or two of arm soreness most people expect after a shot.
How SIRVA Happens
Your deltoid muscle, the rounded muscle at the top of your arm, is the standard target for most vaccines in adults. The correct injection spot sits about two to three fingerbreadths below the bony point at the top of your shoulder, called the acromion process. When a vaccine is administered too high on the arm, closer to or above that bony landmark, or when a needle that’s too long for the patient’s body size is used, the tip can reach structures it was never meant to touch.
The subdeltoid bursa sits just beneath the deltoid and can extend more than 5 centimeters below the acromion. The rotator cuff tendons run through the same area. When vaccine fluid is injected directly into the bursa or around these tendons, it triggers an intense inflammatory response. MRI studies of SIRVA patients show a consistent pattern of damage: erosions of the bone at the top of the arm (the greater tuberosity) appear in roughly 89% of cases, tendon inflammation in about 78%, and joint lining inflammation and bone marrow swelling in over half. Some patients also develop partial tendon tears.
Symptoms and Timeline
The hallmark of SIRVA is shoulder pain that starts quickly after vaccination and doesn’t resolve on a normal timeline. About 54% of patients feel pain immediately during or after the injection. Another 39% notice it within the first 24 hours. By 48 hours, the vast majority of SIRVA cases have declared themselves, which is why compensation guidelines use that window as a cutoff.
Pain is nearly universal, reported by 94% to 100% of patients across multiple studies. But it’s not just soreness. Up to 85% of patients develop limited range of motion, meaning they struggle to lift their arm overhead, reach behind their back, or rotate the shoulder normally. Less common symptoms include tingling or numbness in the arm (about 8% of cases), redness at the injection site (roughly 6%), and general shoulder weakness (about 5%). The key distinction from normal post-vaccine soreness is that SIRVA pain does not respond well to standard over-the-counter pain relievers and persists well beyond the first week.
How SIRVA Differs From Normal Soreness
Almost everyone gets a sore arm after a vaccine. That soreness comes from the immune system responding to the vaccine ingredients in the muscle, and it typically fades within a few days. SIRVA is fundamentally different because the injury is mechanical. The needle physically damages tissue or deposits fluid where it causes direct inflammation of the joint structures.
Clinicians distinguish SIRVA from routine reactions using several criteria: symptoms begin within 24 to 48 hours, pain occurs with movement and limits the arm’s range of motion, imaging shows abnormalities like bursitis or tendon damage, and the pain doesn’t improve with basic painkillers like ibuprofen or acetaminophen. If your shoulder is still painful and stiff a week or more after vaccination, that pattern fits SIRVA more than a typical immune response.
How Common Is It
SIRVA is rare. An analysis of pharmacovigilance data from six countries between 2017 and 2021 estimated the incidence at roughly 2 cases per 10 million vaccine doses. That figure comes from a subset of COVID-19 vaccination data covering nearly 892 million doses, among which 189 SIRVA cases were identified. Earlier estimates had placed the rate much higher, at 25 per 1,000 vaccinations, but those numbers likely reflected reporting inconsistencies and broader definitions of shoulder complaints. Even at 2 per 10 million, with billions of vaccine doses given worldwide, the total number of affected people is meaningful.
Risk Factors and Prevention
The primary risk factor is improper injection technique: injecting too high on the shoulder, using a needle that’s too long for the patient’s body, or failing to identify the correct anatomical landmarks. CDC guidelines specify needle length based on the patient’s weight and sex. Adults under 130 pounds should receive a 1-inch needle, while those over 200 pounds (for women) or over 260 pounds (for men) need a 1.5-inch needle. Using a 1.5-inch needle on a smaller person significantly increases the risk of over-penetration.
Shorter, thinner individuals and those with less muscle mass over the shoulder may be more vulnerable simply because there’s less tissue separating the skin from the bursa and rotator cuff. One MRI-based study found that using a half-inch needle inserted perpendicular to the skin at two fingerbreadths below the acromion achieved a 100% success rate for hitting the deltoid muscle. The axillary nerve, which controls deltoid function, has been found as close as 5 centimeters below the acromion in some people, so injecting too low carries its own risks. The safe zone is relatively narrow.
Diagnosis
There is no single blood test for SIRVA. Diagnosis relies on the clinical story (rapid onset of shoulder pain after vaccination that doesn’t resolve) combined with imaging. MRI is the most informative tool. In chronic SIRVA cases, MRI commonly reveals bone erosions at the greater tuberosity, inflamed tendons (particularly the infraspinatus tendon), joint capsule inflammation, and bone marrow edema. Glenohumeral joint effusion, or fluid accumulation in the shoulder joint, appears in about a third of cases. Subdeltoid bursitis, once considered the signature finding, actually shows up less consistently than bone and tendon changes in chronic cases.
Because these imaging findings overlap with conditions like rotator cuff tears and adhesive capsulitis (frozen shoulder), the timing is what clinches the diagnosis. A shoulder that was completely fine before vaccination and symptomatic within 48 hours afterward points strongly to SIRVA, especially when imaging confirms structural inflammation.
Treatment and Recovery
The vast majority of SIRVA patients, about 94% in one retrospective study, are treated without surgery. The standard approach combines pain relievers, anti-inflammatory medications, and physical therapy to gradually restore range of motion and strength. Most people start with this combination and continue for several months.
When first-line treatment isn’t enough, corticosteroid injections into the shoulder can help reduce inflammation. In the same study, three of sixteen patients needed steroid injections, and one received hydrodilatation, a procedure where fluid is injected into the joint capsule to stretch it. None of the patients in that group required surgery, which is encouraging. However, about 31% of patients still had no meaningful improvement after an average of 12 months, and some were referred to specialists for further evaluation.
Recovery timelines vary widely. Some people improve within a few months of consistent physical therapy. Others deal with pain and stiffness for a year or more. The earlier treatment begins, the better the outcomes tend to be, so persistent shoulder symptoms after a vaccination shouldn’t be dismissed as normal soreness that will resolve on its own.
Filing a Compensation Claim
In the United States, SIRVA is listed on the Vaccine Injury Table maintained by the Health Resources and Services Administration. This means it’s officially recognized as a vaccine-related injury eligible for compensation through the National Vaccine Injury Compensation Program (VICP). To qualify, your symptoms must have started within 48 hours of vaccination, and the effects must have lasted more than 6 months, resulted in hospitalization and surgery, or resulted in death.
Claims must be filed within 3 years of the first symptom. The filing requires documentation of who was injured, which vaccine was given, when and where it was administered, the type of injury, when symptoms first appeared, and how long they lasted. Because SIRVA is on the Injury Table with a defined onset window, the program presumes the vaccine caused the injury unless another explanation is found. This makes SIRVA claims more straightforward than injuries not listed on the table, though the process still requires medical records and often legal guidance.